Abstract：
OBJECTIVE: To describe the population to which we administered recombinant erythropoietin and to determine the effectiveness of this treatment as quantified by the change in hematocrit.
METHODS: This retrospective chart review study included infants who received erythropoietin for the treatment of anemia of prematurity.
RESULTS: There were 132 infants representing 162 unique treatment courses included in the study. The average duration of therapy was 9 days (±7) and 6 doses (±2). The average change in hematocrit (Hct) was 6.2% (SD 3.9%, p < 0.001). Rise in Hct was associated with a higher number of rEPO doses (p < 0.001) and higher postmenstrual age (p < 0.001). In our small cohort we did not find an association between the number of rEPO doses and retinopathy of prematurity (ROP) requiring treatment.
CONCLUSIONS: Erythropoietin is safe and effective at treating anemia of prematurity as evidenced by a clinically and statistically significant increase in Hct from baseline.
METHODS: This retrospective chart review study included infants who received erythropoietin for the treatment of anemia of prematurity.
RESULTS: There were 132 infants representing 162 unique treatment courses included in the study. The average duration of therapy was 9 days (±7) and 6 doses (±2). The average change in hematocrit (Hct) was 6.2% (SD 3.9%, p < 0.001). Rise in Hct was associated with a higher number of rEPO doses (p < 0.001) and higher postmenstrual age (p < 0.001). In our small cohort we did not find an association between the number of rEPO doses and retinopathy of prematurity (ROP) requiring treatment.
CONCLUSIONS: Erythropoietin is safe and effective at treating anemia of prematurity as evidenced by a clinically and statistically significant increase in Hct from baseline.
摘要：
目的：描述我们给药重组促红细胞生成素的人群，并通过血细胞比容的变化来确定这种治疗的有效性。
方法：本回顾性研究包括接受促红细胞生成素治疗早产儿贫血的婴儿。
结果：研究中包括132名婴儿，代表162个独特的治疗疗程。治疗的平均持续时间为9天(±7)和6剂(±2)。血细胞比容（Hct）的平均变化为6.2％（SD3.9％，p<0.001)。Hct升高与更高的rEPO剂量（p<0.001）和更高的月经后年龄（p<0.001）相关。在我们的小队列中，我们没有发现rEPO剂量与需要治疗的早产儿视网膜病变（ROP）之间的关联。
结论：促红细胞生成素在治疗早产儿贫血方面是安全有效的，Hct在临床上和统计学上均较基线显著增加。
方法：本回顾性研究包括接受促红细胞生成素治疗早产儿贫血的婴儿。
结果：研究中包括132名婴儿，代表162个独特的治疗疗程。治疗的平均持续时间为9天(±7)和6剂(±2)。血细胞比容（Hct）的平均变化为6.2％（SD3.9％，p<0.001)。Hct升高与更高的rEPO剂量（p<0.001）和更高的月经后年龄（p<0.001）相关。在我们的小队列中，我们没有发现rEPO剂量与需要治疗的早产儿视网膜病变（ROP）之间的关联。
结论：促红细胞生成素在治疗早产儿贫血方面是安全有效的，Hct在临床上和统计学上均较基线显著增加。
